Clinical trial · Interventional
Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors
NCT02045719CI-TRIAL-00013569cat´sclawunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cat's claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and antitumor properties. Patients and methods: This prospective phase II study will assess the effects of a 100-mg dose of a dry extract of U. tomentosa three times per day on individuals with advanced solid tumors, with no further therapeutic options and with at least 2 months life expectancy. In addition, several biochemical and inflammatory parameters will be analyzed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| uncaria tomentosa (cat´s claw) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- cat's claw
- description
- 100 mg dose of a dry extract of U. tomentosa three times per day
- interventionNames
- Drug: uncaria tomentosa (cat´s claw)
Primary outcomes (1)
- measure
- assessment of benefits on quality of life after treatment during two months
- timeFrame
- two months
- description
- Assess the efficacy and safety of a dry extract of U. tomentosa on individuals who had solid tumors with no further therapeutic options
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * individuals with advanced solid tumors, with no further therapeutic options and with at least 2 moths life expectancy * individuals 18 years of age and older * creatinine levels up to twice the upper limit of normal (ULN) * alanine (ALT) and aspartate (ASP) transaminase levels up to twice the ULN and direct bilirubin (DB) levels up to 1.5 times the ULN * in cases with pre-existing liver disease, the ALT, ASP and DB levels could be up to 2.5 times the ULN Exclusion Criteria: * pregnant and breastfeeding women * individuals using chemotherapy or other tumor-targeting antineoplastic treatments, except for antalgic radiotherapy * severe kidney or liver failure * known hypersensitiveness to the components of the medication used * past history of emotional disorders that could interfere with the data collection.
References
Publications (0)
Data not yet available
No reference posted for this study.